| Description: |
Vitiligo is a hypopigmentation disorder characterized by progressive melanocyte loss that manifest into white macules of the skin, mucosa, or hair. Prevalence of vitiligo in Asia is only known 8,8% in India and 0,09-0,019% in China, while in Indonesia has not found certain. Vitiligo is treated by inhibiting the immune response so reducing melanocyte damage and enhancing the epidermal repopulation by melanocyte either by stimulating the recovery of damaged melanocytes, reactivating residual melanocyte or stimulating melanocyte migration such as corticosteroids, calcineurin inhibitors, antioxidants, phototherapy, and additional therapies such as sunscreen. This study aimed to analyze the utilization of drug in vitiligo including type drug, route of administration, dose, frequency, length of therapy in vitiligo and also identify their adverse effect. This study was retrospective method at period 1 January 2012 until 31 December 2017. Furthermore, this study has been reviewed by The Ethic Committee of Dr. Soetomo Teaching Hospital Surabaya. There were 100 patients who met the sample criteria. The result showed that 97% patients received corticosteroid topical, 94% patients received sunscreen, 7% patients received calcineurin inhibitor topical, and 23% received additional therapy. The type treatment given is varied in patient depend on their condition. From this study, the utilization of treatment in vitiligo was appropriate with condition of each patient. Further study on vitiligo treatment needed follow up to identify its efficacy and DRPs. |